Why the study?
NAFLD is an increasingly common, typically silent condition affecting >25% of adults worldwide and serves as a risk factor for atherosclerotic cardiovascular disease, the principal cause of death in these patients.
This AHA scientific statement emphasizes that NAFLD is a major risk factor for atherosclerotic cardiovascular disease, which is the leading cause of death in these patients.
Answers are grounded in this paper and cite their sources.
Clinicians should integrate NAFLD into ASCVD risk stratification and prevention; confirms its status as a key driver of cardiovascular mortality.
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is believed to affect >25% of adults worldwide. Unless specific testing is done to identify NAFLD, the condition is typically silent until advanced and potentially irreversible liver impairment occurs. For this reason, the majority of patients with NAFLD are unaware of having this serious condition. Hepatic complications from NAFLD include nonalcoholic steatohepatitis, hepatic cirrhosis, and hepatocellular carcinoma. In addition to these serious complications, NAFLD is a risk factor for atherosclerotic cardiovascular disease, which is the principal cause of death in patients with NAFLD. Accordingly, the purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: